Deals•Jan 27, 2026
Siegfried Acquires Noramco Group's API Assets, Enabling Halo Pharma's Standalone CDMO Transition
SK Capital Partners has agreed to sell the active pharmaceutical ingredient (API) assets of the Noramco Group to Swiss contract manufacturer Siegfried, as announced in a Jan 27 2026 press release. The divestiture allows Halo Pharma to become a dedicated North American drug product CDMO, focusing on sterile fill/finish capabilities. The transaction was disclosed on Jan 27 2026.
Pharmaceutical Technology
Deals•Jan 26, 2026
Mirum Pharmaceuticals Acquires Bluejay Therapeutics, Adding Brelovitug for HDV
Mirum Pharmaceuticals completed its acquisition of Bluejay Therapeutics, adding the Phase 3 antibody brelovitug for chronic hepatitis delta virus (HDV) to its pipeline. The deal integrates Bluejay’s team and assets, aiming to finish the AZURE Phase 3 program and prepare for potential...
Pharmaceutical Technology
Blog•Jan 7, 2026
Behind the Headlines Episode 31: Optimism, Opportunity, Optimization of COGs & Organizational Streamlining
In the Behind the Headlines Episode 31, veteran pharma leader Deborah Dunsire declares a "golden era" for biological sciences, driven by targeted therapies such as GLP‑1s and emerging tools like AI and quantum computing. She stresses the need for fact‑based communication...
By Pharmaceutical Technology
Blog•Jan 7, 2026
The New Subcutaneous (SC) Landscape: Adapting Drug Delivery for Biologics Administration at Home
The pharmaceutical sector is rapidly transitioning high‑value biologics from clinic‑based IV infusions to at‑home subcutaneous (SC) self‑administration. Datwyler’s upcoming event will dissect market forces behind this shift, emphasizing challenges such as drug viscosity, volume limits, and component compatibility. Speakers will...
By Pharmaceutical Technology
Blog•Jan 6, 2026
Amgen Acquires UK Biotech Dark Blue Therapeutics
Amgen announced a $840 million acquisition of UK‑based Dark Blue Therapeutics, adding an investigational small‑molecule that degrades MLLT1/3 proteins implicated in acute myeloid leukemia (AML). The deal expands Amgen’s targeted‑protein‑degradation platform and strengthens its oncology pipeline with a novel mechanism to overcome...
By Pharmaceutical Technology
Blog•Jan 6, 2026
Industry Outlook 2026: Trends Transitioning From 2025 Into 2026
Pharma firms widely adopted AI, IoT and digitalization in 2025, and those tools will dominate 2026. Real‑time process monitoring and predictive analytics have become competitive necessities, according to Ecolab Bioprocessing’s Laine Mello. The surge in complex biologics, cell and gene...
By Pharmaceutical Technology
Blog•Jan 6, 2026
Genetic Medicines Project Gets Funding From UKRI Innovate UK and Canadian NRC IRAP
Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals announced a joint genetic‑medicine project funded by UKRI Innovate UK and Canada’s NRC IRAP. The partnership merges Chromatin Bioscience’s chromatinLENS synthetic‑promoter platform, Mediphage’s msDNA linear DNA technology, and Entos’s Fusogenix PLV fusion‑based delivery system....
By Pharmaceutical Technology
Blog•Jan 5, 2026
China Clears Mepolizumab for COPD
China’s National Medical Products Administration approved GSK’s mepolizumab (Nucala) as an add‑on maintenance therapy for adults with eosinophilic COPD, making it the first monthly biologic for the disease in the country. The decision rests on Phase III MATINEE and METREX trials...
By Pharmaceutical Technology
Blog•Jan 5, 2026
Making Smart Decisions and Investments in Trained Staff Key to 2026 Success
Raj Puri, chief commercial officer of Argonaut Manufacturing, warns that U.S. tariffs will keep pressuring pharma manufacturers in 2026, extending costs and timelines for new or upgraded facilities. He highlights that large capital projects face uncertainty in a volatile geopolitical...
By Pharmaceutical Technology
Blog•Jan 5, 2026
Quick Execution with Operational Integrity
Meri Beckwith, Co‑CEO of Lindus Health, outlines how 2025 trends will shape pharma in 2026. AI moved from experimental to strategic, accelerating trial design, site selection and patient matching. Decentralized trial models combined with real‑world data enable nationwide recruitment and...
By Pharmaceutical Technology
Blog•Jan 5, 2026
FUJIFILM Irvine Scientific Becomes FUJIFILM Biosciences
FUJIFILM Irvine Scientific rebranded as FUJIFILM Biosciences on Jan. 1, 2026, aligning its name with a 55‑year legacy in cell‑culture media and bioprocessing. The change underscores the unit’s shift toward biologics manufacturing and CDMO services. Recent strategic moves include a $3 billion, 10‑year...
By Pharmaceutical Technology
Blog•Jan 5, 2026
Advancing Pharmaceutical Quality Through Integrated Digital Systems and Collaborative Scientific Innovation
Saharsh Davuluri of Neuland Labs outlines a digital overhaul of API manufacturing, leveraging AI tools such as Merck’s Synthia and automated parallel synthesizers to design scalable processes. He envisions a fully paperless plant where electronic batch records feed directly into...
By Pharmaceutical Technology
Blog•Jan 5, 2026
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 2: A Detailed Assessment for Specification Equivalence
The article presents a technical assessment of compendial tests across the European Pharmacopoeia, USP‑NF, and Japanese Pharmacopoeia to establish specification equivalence for pharmaceutical excipients. It recommends standardizing on the Ph. Eur. method for most tests, applying the tightest acceptance criteria, and...
By Pharmaceutical Technology
Blog•Jan 2, 2026
Industry Outlook 2026: Success Through Top Talent, AI Utilization, and Sustainability
Ardena US managing director Ian Bilodeau says AI is reshaping pharma by linking fragmented data and speeding product decisions. He also emphasizes that attracting and developing top talent requires challenging, impact‑focused work environments. Sustainability, highlighted by Ardena’s EcoVadis certification, is...
By Pharmaceutical Technology
Blog•Jan 2, 2026
The Evolution of Data-First Regulatory Operations
Remco Munnik of Arcana Life Sciences says European regulators are cementing a data‑first approach, with the EMA’s electronic product database and digital submission forms becoming standard. The pharma sector is eager to embed AI for document automation and quality oversight,...
By Pharmaceutical Technology
Blog•Jan 2, 2026
Double Cone Tumble Blender Provides Homogeneity in Heavy-Duty Applications
Charles Ross & Son introduced the DCB-5 Double Cone Tumble Blender, a five‑cubic‑foot unit designed for high‑density powder processing. The machine combines a stainless‑steel jacket, a 2 HP intensifier bar, and an integrated vacuum system to deliver repeatable homogeneity and simultaneous...
By Pharmaceutical Technology
Blog•Jan 2, 2026
From AI to Smart Factories: How Pharma Is Preparing for 2026
Manish Garg of Hikma Pharmaceuticals highlighted how AI, personalized medicine, and smart manufacturing reshaped pharma in 2025 and set the agenda for 2026. AI accelerated drug discovery and clinical design, while niche, high‑value therapies gained prominence. Companies are regionalizing supply...
By Pharmaceutical Technology
Blog•Jan 1, 2026
HITL and HOTL: An Air Traffic Control Analogy for Agentic AI
ArisGlobal’s senior VP Jason Bryant argues that both human‑in‑the‑loop (HITL) and human‑on‑the‑loop (HOTL) remain essential for deploying agentic AI in pharma. He uses an air‑traffic‑control analogy, portraying AI agents as aircraft and the orchestration layer as air‑traffic management. Bryant stresses...
By Pharmaceutical Technology
Blog•Dec 30, 2025
Industry Outlook 2026: The Impact of Novel Therapies
In 2025 the pharmaceutical sector saw a surge of novel therapies, notably next‑generation biologics such as bispecifics, fusion proteins, multi‑specifics, and a wave of antibody‑drug conjugates (ADCs). A breakthrough sub‑category, antibody‑oligo conjugates (AOCs), gained traction for muscular dystrophy, highlighted by...
By Pharmaceutical Technology
Blog•Dec 29, 2025
Full Autonomy Is a ‘No-Go Zone’: Setting Parameters for Agentic AI in Pharma
ArisGlobal senior VP Jason Bryant explains that full autonomy for AI agents is off‑limits in pharmacovigilance, citing ethical and legal concerns. Instead, he advocates bounded autonomy managed by an orchestrator that can hand control to humans when needed. The discussion...
By Pharmaceutical Technology
Blog•Dec 28, 2025
Navigating Digitalization, QRM Maturity, and Global Compliance Convergence Into 2026
Henrik Johanning of Epista Life Sciences outlines the European regulatory and manufacturing roadmap for 2026, emphasizing the operationalisation of modern quality risk management (QRM) and the need for tangible upgrades to meet EU GMP Annex 1 requirements. He highlights rising digital...
By Pharmaceutical Technology
Blog•Dec 28, 2025
The Top 10 PharmTech Videos of 2025
The PharmTech roundup reviews the ten most‑watched videos of 2025, revealing a industry pivot toward complex modalities such as AAV‑based gene therapies, high‑concentration biologics, and radiopharmaceuticals. Across the series, manufacturers stress the "CGT 2.0" model—flexible, automated, data‑driven production—to overcome scale‑up bottlenecks....
By Pharmaceutical Technology